17797-12-5

Basic information

• Product Name: 1-(4-Bromophenyl)-1-methylethylamine
• Synonyms: 1-(4-BROMOPHENYL)-1-METHYLETHYLAMINE;1-(1-Amino-1-methylethyl)-4-bromobenzene;2-(4-bromophenyl)propan-2-amine;2-(4-BroMophenyl)propan-2-aMine hydrochloride;4-Bromo-alpha,alpha-dimethylbenzylamine;2-(4-bromophenyl)propan-2-amine(WXC06369)
• CAS NO: 17797-12-5
• Molecular Formula: C₉H₁₂BrN
• Molecular Weight: 214.1
• Mol File: 17797-12-5.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 268 °C
• Flash Point: 116 °C
• Appearance: /
• Density: 1.342
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.15±0.10(Predicted)
• CAS DataBase Reference: 1-(4-Bromophenyl)-1-methylethylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Bromophenyl)-1-methylethylamine(17797-12-5)
• EPA Substance Registry System: 1-(4-Bromophenyl)-1-methylethylamine(17797-12-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 17797-12-5(Hazardous Substances Data)

Usage

Uses

2-(4-Bromophenyl)propan-2-amine acts as a reagent for the synthesis of biaryl diamides as potent melanin concentrating hormone receptor 1 antagonist.

InChI:InChI=1/C9H12BrN/c1-9(2,11)7-3-5-8(10)6-4-7/h3-6H,11H2,1-2H3

Upstream product

• 623-00-7 4-bromobenzenecarbonitrile 
• 917-54-4 methyllithium 
• 16532-79-9 4-Bromophenylacetonitrile 
• 75-16-1 methylmagnesium bromide 
• 2077-19-2 2-(4-bromophenyl)propan-2-ol 
• 64586-24-9 N-(p-Brom-α,α-dimethylbenzyl)formamid 
• 586-61-8 4-iso-propylbromobenzene 

Downstream Products

• 214973-83-8 tert-butyl (2-(4-bromophenyl)propan-2-yl)carbamate 
• 1263077-30-0 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-amine 
• 1263076-97-6 7-[4-(2-aminopropan-2-yl)phenyl]-5-(ethylamino)-3-methyl-3H,4H-pyrido[4,3-d]pyrimidin-4-one 
• 494773-23-8 4-(2-(4-bromophenyl)propan-2-yl)morpholine 

Relevant articles and documents

METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES

Methods are provided for treating or preventing neurological symptoms and disorders which are associated with, e.g., lysosomal storage diseases. The methods include enhancing neuronal connectivity within the brain of a subject, increasing brain tissue volume, or preventing or delaying loss of brain tissue volume in a subject. Also provided are methods for monitoring the progression or regression of a neurological disorder, or assessing the onset of a neurological disorder, associated with a lysosomal storage disease, in which brain tissue volume of the subject is measured.

METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES

This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes pain, such as abdominal pain, and dermatological disorders, such as angiokeratoma, in a patient having a disease such as Fabry disease. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.